Novartis: progress reports at upcoming congresses

(CercleFinance.com) - Novartis today announced that it will present data from 17 abstracts - including investigator-initiated trials - across its immunology portfolio at the American Academy of Allergy Asthma and Immunology (AAAAI) and World Allergy Organization (WAO) Joint Meeting 2025 and the American Academy of Dermatology (AAD) Annual Meeting 2025.


Data include analyses of long-term urticaria control, sleep and activity from two Phase III studies evaluating investigational remibrutinib for the treatment of chronic spontaneous urticaria (CSU).

In addition, long-term data from phase III trials of Cosentyx (secukinumab) in patients with hidradenitis suppurativa (HS) and patient-reported results from a phase II trial evaluating remibrutinib in HS will be presented.

The company says these data will support regulatory submissions in H1 2025.


Copyright (c) 2025 CercleFinance.com. All rights reserved.